Publication

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

Journal Paper/Review - Jun 25, 2015

von Minckwitz Gunter, Thomssen Christoph, Huober Jens, Denkert Carsten, Alfer Joachim, Jackisch Christian, Nekljudova Valentina, Burchardi Nicole, Loibl Sibylle, Simon Eike, Stickeler Elmar, Potenberg Jochem, Conrad Bettina, Reimer Toralf, Decker Thomas, Eidtmann Holger, Eiermann Wolfgang, Hackmann John, Möbus Volker, Marme Frederik, German Breast Group Investigators